Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XR 303

Next Previous
X
Search
Drug Profile

XR 303

Alternative Names: Anti-CEA sheep monoclonal antibody - KS Biomedix Holdings; Anti-CEA sheep monoclonal antibody 6H9; KAb201; KS 6H9Chi; KSB 303; KSB-303C; KSB-303P; Sheep anti-CEA monoclonal antibody - KS Biomedix Holdings; SMA CEA - KS Biomedix Holdings; XR303

Latest Information Update: 13 Sep 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cancer Research UK; Xenova Group
  • Developer Celtic Pharma
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Pancreatic cancer

Most Recent Events

  • 13 Sep 2010 Discontinued - Phase-I for Colorectal cancer in Malaysia (Parenteral)
  • 13 Sep 2010 Discontinued - Phase-I/II for Pancreatic cancer in Europe (Parenteral)
  • 08 Aug 2007 XR 303 is still in phase I/II trials for Pancreatic cancer in Europe

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top